CVE-2018-18977
An attacker may reverse engineer the codebase to extract sensitive data that contributes to the disclosure of medical information of patients utilizing the Ascensia platform.
Does this matter?
High impact if exploited, but EPSS currently rates exploitation as unlikely (1.58%). Schedule it in the normal patch cycle and watch for a rise in EPSS or a public exploit.
Description
An issue was discovered in the Ascensia Contour NEXT ONE application for Android before 2019-01-15. An attacker may reverse engineer the codebase to extract sensitive data that contributes to the disclosure of medical information of patients utilizing the Ascensia platform. This occurs because of weak obfuscation.
- CVSS 3.0
- 7.5 HIGHCVSS:3.0/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N
- EPSS
- 1.58% probability · 75th percentile
- Public exploits
- None in Exploit-DB
- CISA KEV
- Not listed
- Weakness
- CWE-200
- Affected
- ascensia/contour diabetes
- Source
- cve@mitre.org
EPSS 1.6% since 27 October 2026; no change recorded yet. Points are recorded when the score first appears and whenever it moves by a percentage point or more.
References
- https://depthsecurity.com/blog/medical-exploitation-you-are-now-diabeticExploit, Third Party Advisory
- https://depthsecurity.com/blog/medical-exploitation-you-are-now-diabeticExploit, Third Party Advisory
Source: NVD record, EPSS from FIRST.org, KEV from CISA, exploits from Exploit-DB. Refreshed daily. Download this record as JSON.